TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
05/20/2025
Back to search
Official data from USPTO
MAZE THERAPEUTICS
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: WordOffice: US
Quick snapshot
MAZE THERAPEUTICS
ST13
US500000088918255Class
5
Filing
88918255
Registration
7475338
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
49
Latest update
05/25/2025
Classification
Registered
Trademark type
Word
Nice classes
5
Filing date
05/15/2020
Registration date
08/13/2024
Expiration date
-
Recommended action
Perform a full collision analysis and validate classes before any filing or trademark investment.
Next step
These are the details of the registration process. Even so, constant monitoring is what ensures peace of mind that your main asset remains protected.
Complete case details
Structured fields from the responsible authority and the official record.
Status date
08/13/2024
Last transaction
05/25/2025
Responsible office
United States Patent and Trademark Office
Status code
700
Official register
Principal Register
Filing basis
Intent to use
First use anywhere
2022-01-00
First use in commerce
2022-01-00
Drawing code
4
Owner type
03
Owner location
San Francisco, CA
Examiner
LIEBL, ALEXANDRA
Law office
N20
Current location
PUBLICATION AND ISSUE SECTION
Holders and representatives
Holders
Maze Therapeutics, Inc.
Maze Therapeutics, Inc.
Representatives
Joyce Liou Morrison & Foerster LLP
Technical classification
Nice Classes
Class 5
Vienna Codes
No Vienna codes available.
Goods and services
Class 5
Pharmaceutical preparations for treating genetic diseases and disorders pharmaceutical preparations for the treatment of diseases and disorders of the metabolic system; pharmaceutical preparations for the treatment of heart diseases and disorders; pharmaceutical preparations for the prevention and treatment of kidney diseases; pharmaceutical preparations for the treatment of diabetes; reagents for medical use
Publications
History of USPTO decisions and trademark events.
49 publications found
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
05/20/2025
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
05/20/2025
CHAN
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
05/20/2025
COAR
TEAS CHANGE OF OWNER ADDRESS RECEIVED
05/20/2025
NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
08/13/2024
R.PR
REGISTERED-PRINCIPAL REGISTER
08/13/2024
SUNA
NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
07/08/2024
CNPR
ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
07/08/2024
SUPC
STATEMENT OF USE PROCESSING COMPLETE
06/05/2024
IUAF
USE AMENDMENT FILED
05/28/2024
EISU
TEAS STATEMENT OF USE RECEIVED
05/28/2024
EXRA
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
11/01/2023
EX5G
SOU EXTENSION 5 GRANTED
10/31/2023
AITU
CASE ASSIGNED TO INTENT TO USE PARALEGAL
10/31/2023
EXT5
SOU EXTENSION 5 FILED
10/25/2023
EEXT
SOU TEAS EXTENSION RECEIVED
10/25/2023
EXRA
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
05/10/2023
EX4G
SOU EXTENSION 4 GRANTED
05/08/2023
EXT4
SOU EXTENSION 4 FILED
05/08/2023
EEXT
SOU TEAS EXTENSION RECEIVED
05/08/2023
EXRA
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
11/24/2022
EX3G
SOU EXTENSION 3 GRANTED
11/22/2022
EXT3
SOU EXTENSION 3 FILED
11/22/2022
EEXT
SOU TEAS EXTENSION RECEIVED
11/22/2022
EXRA
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
05/25/2022
EX2G
SOU EXTENSION 2 GRANTED
05/23/2022
EXT2
SOU EXTENSION 2 FILED
05/23/2022
EEXT
SOU TEAS EXTENSION RECEIVED
05/23/2022
EXRA
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
11/17/2021
EX1G
SOU EXTENSION 1 GRANTED
11/15/2021
EXT1
SOU EXTENSION 1 FILED
11/15/2021
EEXT
SOU TEAS EXTENSION RECEIVED
11/15/2021
NOAM
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
05/25/2021
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
03/30/2021
PUBO
PUBLISHED FOR OPPOSITION
03/30/2021
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
03/10/2021
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
02/19/2021
XAEC
EXAMINER'S AMENDMENT ENTERED
02/19/2021
GNEN
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
02/19/2021
GNEA
EXAMINERS AMENDMENT E-MAILED
02/19/2021
CNEA
EXAMINERS AMENDMENT -WRITTEN
02/19/2021
DOCK
ASSIGNED TO EXAMINER
11/02/2020
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
08/20/2020
GNRT
NON-FINAL ACTION E-MAILED
08/20/2020
CNRT
NON-FINAL ACTION WRITTEN
08/20/2020
DOCK
ASSIGNED TO EXAMINER
08/13/2020
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
05/29/2020
NWAP
NEW APPLICATION ENTERED
05/19/2020
Continuous trademark protection
Get notified about every new filing that threatens MAZE THERAPEUTICS or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.